Sur I’activité anti-arythmique d’un nouvel agent de blocage beta-adrénergique

Abstract

Butydrine (2-sec. butylamino-1-(5,6,7,8-tetrahydro-2-naphtyl) ethanol HCL) was studied in normal subjects and in patients suffering from various types of arrhythmias. The drug apparently has no significant metabolic effect. It causes a mild bradycardia with an increase in both systolic and diastolic arterial pressures. It blocks the metabolic, hemodynamic and arrhythmic effects otherwise elicited by an epinephrine infusion. In atrial fibrillation, the drug leads to a decrease in ventricular rate, even in patients previously digitalized. The combination of butydrine and digitalis is more effective than either drug alone. Butydrine is particularly effective in reverting extrasystoles due to digitalis intoxication. It has little effect in paroxysmal atrial fibrillation and in atrial or ventricular paroxysmal tachycardia. It does not influence the tachycardia due to hyperthyroidism.